Non-EU clinical data can support CE certification under EU MDR 2017/745, but only if it meets the MDR's requirements for relevance, quality, and applicability to the EU population and device as marketed. There is no rule against using data generated for FDA or NMPA approval, but the MDR assesses the evidence itself, not where it was collected.
Does the MDR Reject Data From Outside the EU?
No. The EU MDR imposes no geographic restriction on the origin of clinical data. What it does require is that the evidence, regardless of origin, demonstrates conformity with the relevant General Safety and Performance Requirements (GSPRs).
FDA or NMPA approval alone doesn't satisfy this. The underlying clinical evidence still needs its own appraisal against MDR criteria, independent of any approval it already holds elsewhere.
What Will a Notified Body Assess?
A Notified Body assessing non-EU clinical data checks three things: how rigorously it was collected, whether it transfers to the EU population and clinical setting, and whether it matches the device as marketed in Europe. Each is weighed independently, and weakness in one can't be offset by strength in another.
Was it collected to an acceptable standard?
Data aligned with Good Clinical Practice under ISO 14155, the Declaration of Helsinki, and, where personal data is involved, GDPR carries substantially more weight than data collected to a lower or unclear standard.
Is it transferable to the EU population and clinical setting?
Differences in the standard of care, patient demographics, or clinical practice between the original study population and the EU population can limit the extent to which the results apply. Any such gaps need to be explicitly identified and justified, not left implicit.
Does it match the device as marketed in the EU?
Differences in configuration, intended purpose, or indications between the originally studied device and the EU version need scrutiny, including any reliance on equivalence under MDCG 2020-5.
How Do You Build a Defensible Case?
The strength of a non-EU dataset depends on critical appraisal: assessing each dataset for relevance and quality, then documenting that assessment transparently in the Clinical Evaluation Plan and Report. Where gaps remain, a targeted Post-Market Clinical Follow-Up Plan can bridge them.
Used strategically, non-EU clinical data can meaningfully shorten the route to CE marking. The difference between acceptance and a Notified Body deficiency usually comes down to how rigorously that data is justified, not how much of it exists.
Planning to leverage existing clinical data for the EU market? Our clinical team can help you assess its strength and build a defensible evaluation strategy.
